ANI Pharmaceuticals (ANIP) Marked As A Dead Cat Bounce Stock
Trade-Ideas LLC identified
(
) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified ANI Pharmaceuticals as such a stock due to the following factors:
- ANIP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $21.3 million.
- ANIP has traded 67,724 shares today.
- ANIP is up 6.1% today.
- ANIP was down 10.9% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ANIP with the Ticky from Trade-Ideas. See the FREE profile for ANIP NOW at Trade-Ideas
More details on ANIP:
ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. ANIP has a PE ratio of 14. Currently there are 2 analysts that rate ANI Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for ANI Pharmaceuticals has been 395,200 shares per day over the past 30 days. ANI has a market cap of $512.7 million and is part of the health care sector and drugs industry. The stock has a beta of 3.16 and a short float of 24.4% with 3.81 days to cover. Shares are down 20.6% year-to-date as of the close of trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates ANI Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.
Highlights from the ratings report include:
- ANIP's very impressive revenue growth greatly exceeded the industry average of 3.4%. Since the same quarter one year prior, revenues leaped by 193.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Powered by its strong earnings growth of 247.61% and other important driving factors, this stock has surged by 33.68% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
- ANIP's debt-to-equity ratio of 0.76 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Even though the debt-to-equity ratio shows mixed results, the company's quick ratio of 26.86 is very high and demonstrates very strong liquidity.
- ANI PHARMACEUTICALS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. However, we anticipate underperformance relative to this pattern in the coming year. During the past fiscal year, ANI PHARMACEUTICALS INC turned its bottom line around by earning $2.53 versus -$5.54 in the prior year. For the next year, the market is expecting a contraction of 3.5% in earnings ($2.44 versus $2.53).
- Net operating cash flow has decreased to $1.21 million or 38.28% when compared to the same quarter last year. Despite a decrease in cash flow ANI PHARMACEUTICALS INC is still fairing well by exceeding its industry average cash flow growth rate of -58.99%.
- You can view the full ANI Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.